SubsidieMeestersA metagenomic-based precision-medicine tool for personalized diagnosis, prognosis and treatment of oral diseases
PreBiomicsPMT aims to develop an automated precision-medicine test using metagenomics and AI to assess peri-implant plaque microbiomes, enhancing diagnosis and treatment for dental implant patients.
Projectdetails
Introduction
About 20M dental implants are performed globally per year. The implant market, valued at 3.6B in 2020, is growing at a CAGR of 11%. Unfortunately, microbiome-biofilm-associated diseases can affect dental implants, compromising oral and systemic health.
Challenges in Dental Implants
More than 50% of implant patients develop mucositis, an inflammation of the soft tissues, which may lead to peri-implantitis, a severe infection affecting soft and hard tissues that can lead to implant loss. Currently, there are no reliable tools to assess disease severity and risk of disease progression.
Limitations of Current Approaches
The dentist can only prescribe empirical therapies without knowing the composition of the triggering peri-implant plaque microbiome.
PreBiomics Solution
At PreBiomics, we developed a precision-medicine test that characterizes the microbial composition of the plaque biofilm collected in the area surrounding the implant. In 10 years of research, we have shown that the presence of specific bacteria is key to predicting the infection's severity and progression.
Project Overview
PreBiomicsPMT will develop a test using metagenomics and an AI algorithm, which will enable the implementation of monitoring and diagnosis and provide treatment recommendations for each patient based on the bacterial composition of their plaque microbiome.
Objectives of the EIC-Transition Project
Based on the results of the ERC POCs PB3P, this EIC-Transition project aims to:
- Automate the workflow using a robotic solution to reduce the costs of the service and speed up the results.
- Build an extensive database that will be used to create an antibiotic resistance panel.
- Further develop our decision support system (DSS) for dentists.
- Conduct a validation study to prove the predictive power of our DSS.
Additional Developments
Alongside the technical development, we will:
- Define the IPR management plan to protect the knowledge we continuously generate.
- Study in-depth the dental implants market and the needs and expectations of our customers and investors.
- Elaborate a robust business plan to allow proper exploitation of our product.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.461.900 |
| Totale projectbegroting | € 2.461.900 |
Tijdlijn
| Startdatum | 1-5-2023 |
| Einddatum | 30-4-2026 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- PREBIOMICS SRLpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Transition
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Targeting cardiac fibrosis with next generation RNA therapeuticsFIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness. | EIC Transition | € 2.499.482 | 2022 | Details |
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationSThe NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring. | EIC Transition | € 2.497.750 | 2022 | Details |
Predictive REagent-Antibody Replacement Technology stage 2-TranslationPRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment. | EIC Transition | € 800.000 | 2022 | Details |
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stageDeveloping a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships. | EIC Transition | € 2.499.810 | 2022 | Details |
Targeting cardiac fibrosis with next generation RNA therapeutics
FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationS
The NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring.
Predictive REagent-Antibody Replacement Technology stage 2-Translation
PRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment.
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stage
Developing a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Preclinical validation and market analysis of a microMESH implant for brain cancer eradicationThe project aims to develop and validate a novel drug delivery implant, microMESH, for targeted chemo-immunotherapy in glioblastoma, enhancing treatment efficacy and patient outcomes. | ERC POC | € 150.000 | 2022 | Details |
Bacteria Biofilm as bio-factory for tissue regenerationBIOACTION aims to transform biofilm-associated infections into a resource for tissue regeneration using functionalized bio-hydrogels and engineered liposomes, enhancing implant technology and health outcomes. | EIC Pathfinder | € 2.903.862 | 2023 | Details |
Microbiome-based diagnostics and therapeuticsThis project aims to develop microbiome-based diagnostic and therapeutic products by leveraging multi-omics data to identify predictive bacterial strains for disease onset and progression. | ERC POC | € 150.000 | 2023 | Details |
AmbiJet: the world’s first and only highly effective plasma-based solution for Europe’s 16 Million periimplantitis patients urgently needing help to avoid losing their dental implantAmbiJet is a groundbreaking plasma-based technology that effectively eliminates bacteria on dental implants, preventing reinfection and promoting better oral and overall health. | EIC Accelerator | € 1.389.062 | 2022 | Details |
Preclinical validation and market analysis of a microMESH implant for brain cancer eradication
The project aims to develop and validate a novel drug delivery implant, microMESH, for targeted chemo-immunotherapy in glioblastoma, enhancing treatment efficacy and patient outcomes.
Bacteria Biofilm as bio-factory for tissue regeneration
BIOACTION aims to transform biofilm-associated infections into a resource for tissue regeneration using functionalized bio-hydrogels and engineered liposomes, enhancing implant technology and health outcomes.
Microbiome-based diagnostics and therapeutics
This project aims to develop microbiome-based diagnostic and therapeutic products by leveraging multi-omics data to identify predictive bacterial strains for disease onset and progression.
AmbiJet: the world’s first and only highly effective plasma-based solution for Europe’s 16 Million periimplantitis patients urgently needing help to avoid losing their dental implant
AmbiJet is a groundbreaking plasma-based technology that effectively eliminates bacteria on dental implants, preventing reinfection and promoting better oral and overall health.